29
Jun

Celgene is paying about $1 billion to move to the front of the hectic race to build new CAR-T cancer therapies. The Big Biotech is shelling out $150 million upfront and paying $93 a share–a huge premium–to snap up 9.1 million shares of Juno Therapeutics, inking a collaboration to develop and commercialize new oncology therapies.

…read more

Source: UPDATED: Celgene pays $1B in landmark deal to buy into Juno’s pipeline of CAR-T drugs

    

0 No comments